

**Figure S1**. b-pEPCs promoted angiogenesis in vivo. Co-staining of CD31 and PCNA to measure proliferative endothelial cells (white triangles). In healthy kidney, endothelial cells are mostly at resting status, only a few cells keep proliferating. IR led to endothelial cell apoptosis and vascular injury, which activate endothelial cells for self-repair, the histogram showed that on IR-day5, the proliferative endothelial cells in the IR group was at the same level as in sham groups. In IR+b-pEPCs group, they were still at a rather higher proliferative state. The data were presented as the mean  $\pm$  SD, n=3-4/group, \*p<0.05, \*\*p<0.01, ns: no significant difference. Scale bar: 50 µm.



**Figure S2.** Bone marrow-derived cells (BMCs) differentiated into endothelial cells and participated in angiogenesis. **A.** The scheme of bone marrow transplantation (BMT). GFP-labelled BMCs were tracked in IR operated mice. Co-staining of GFP and CD31 meant that exogenous BMCs expressed CD31 in injured kidney. Co-staining of GFP and PDGFR- $\beta$  presented GFP positive b-pEPCs located attached with PDGFR- $\beta$  positive pericytes. **B.** The scheme of conjoined parabiosis. Co-staining showed that cells from healthy mice were recruited to the injured kidney and expressed endothelial cell marker CD31. Co-staining of GFP and PDGFR- $\beta$  implied the location of exogenous b-pEPCs was close to pericytes. Both results implied that BMCs owned the capacity of differentiation into endothelial cells and participated in angiogenesis. Scale bar: 20 µm.



**Figure S3.** Tracking of b-pEPCs in injured kidney. **A.** The Scheme of this part. **B.** The gating strategy and images from cytometer. **C.** b-pEPCs isolated from EGFP mice were transplanted into mice after IR surgery. b-pEPCs calculation was measured in IR-day 10. Both CD34-positive cells and GFP-positive cells were counted by flow cytometry to track exogenous b-pEPCs in IR-operated kidney. The data were presented as the mean  $\pm$  SD, n=3-5/group, \*p<0.05, ns: no significant difference.



**Figure S4.** b-pEPCs promoted angiogenesis in vitro. **A.** Scheme of culture and stimulation of human umbilical vein endothelial cells (HUVECs) in vitro. **B.** immunofluorescent staining of HUVECs. In HUVECs+H<sub>2</sub>O<sub>2</sub> group, the number of endothelial cells significantly decreased compared to HUVECs group. With the b-pEPCs-CM treatment, the number increased, and cells distributed in tube formation shape. Scale bar: 20µm. **C.** 3D-tube formation test showed endothelial cells formatted in tube shape. H<sub>2</sub>O<sub>2</sub> damaged this ability and cells scattered in the Matrigel. In HUVECs+H<sub>2</sub>O<sub>2</sub>+b-pEPCs-CM group, part of the cells preserved the tube formation ability. Scale bar: 10 µm. The data were presented as the mean  $\pm$  SD, n=3-4/group, \**p*<0.05.



**Figure S5.** b-pEPCs-CM had an equivalent protective effect on IR-induced renal injury and fibrosis as b-pEPCs. **A.** The Scheme of this part. **B.** Serum BUN and creatinine detected by biochemical kit. **C.** Pathological staining and statistical histograms. The data were presented as the mean  $\pm$  SD, n=4-5/group, ns: no significant difference, \**p*<0.05, \*\**p*<0.01. Scale bar: 50 µm.



**Figure S6.** Pericyte-myofibroblast transition. Co-staining of collagen 1 $\alpha$ 1 and PDGFR- $\beta$  to measure pericyte-derived myofibroblast. The ratio of collagen 1 $\alpha$ 1+PDGFR- $\beta$ +/collagen 1 $\alpha$ 1+ area was to further calculate the portion of myofibroblast derived from pericyte. The data were presented as the mean  $\pm$  SD, n=4/group, \*p<0.05, \*\*p<0.01. Scale bar: 50 µm.

qRT-PCR



**Figure S7.** IR increased the expression of PDGFs. Analysis of PDGFR- $\beta$ ' ligands by qRT-PCR. The data were presented as the mean  $\pm$  SD, n=3-5/group, \**p*<0.05.



**Figure S8.** PDGF-BB increased the expression of PDGFR- $\beta$  positive pericytes and exacerbated renal fibrosis, which was ameliorated by b-pEPCs. **A.** Histogram of PAS and Masson staining in Figure 5C. **B.** The measurement of fibrotic markers  $\alpha$ -SMA and Fibronectin in RNA level by qRT-PCR. The data were presented as the mean  $\pm$  SD, n=3-5/group, \**p*<0.05, \*\**p*<0.01.



**Figure S9.** The protective effect of b-pEPCs on vascular injury and renal fibrosis was blocked by PDGFR- $\beta$  positive pericyte depletion. **A and B.** Western blot and qRT-PCR to analyze PDGFR- $\beta$  expression. **C.** Assessment of renal fibrosis with fibrotic markers  $\alpha$ -SMA and Fibronectin in protein level. **D.** Co-staining of PDGFR- $\beta$  with PCNA and  $\alpha$ -SMA to check pericyte status of proliferation and transition. The data were presented as the mean  $\pm$  SD, n=4/group, ns: no significant difference, \**p*<0.05. Scale bar: 50 µm.



**Figure S10**. DT deleted PDGFR- $\beta$  positive pericyte and ameliorated pericyte-myofibroblast transition. Existed fibrosis can't be reverted by DT injection 2 days after IR surgery. **A.** The scheme of this part. **B and C.** Pathological staining (PAS and Masson) to evaluate tubular injury and renal fibrosis in DTR-PD mice with or without DT injection before or after IR surgery. PDGFR- $\beta$  was measured to observe the number of pericyte. The data were presented as the mean  $\pm$  SD, n=3-5/group, ns: no significant difference, \*p<0.05, \*\*p<0.01. Scale bar: 50 µm.